Pazopanib as third-line therapy for metastatic renal cell carcinoma: Clinical efficacy and temporal analysis of cytokine profile

被引：0
|
作者：
Pal, Sumanta K. [1 ]
Hossain, Dewan Md Sakib [1 ]
Zhang, Qifang [1 ]
Gao, Chan [1 ]
Jones, Jeremy O. [1 ]
Frankel, Paul H. [1 ]
Figlin, Robert A. [2 ]
Kortylewski, Marcin [1 ]
机构：
[1] City Hope Natl Med Ctr, Ctr Comprehens Canc, Duarte, CA USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT334
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pazopanib as Third Line Therapy for Metastatic Renal Cell Carcinoma: Clinical Efficacy and Temporal Analysis of Cytokine Profile
    Pal, Sumanta Kumar
    Hossain, Dewan Md Sakib
    Zhang, Qifang
    Frankel, Paul Henry
    Jones, Jeremy O.
    Carmichael, Courtney
    Ruel, Christopher
    Lau, Clayton
    Kortylewski, Marcin
    JOURNAL OF UROLOGY, 2015, 193 (04): : 1114 - 1121
  • [2] Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
    Roberto, Michela
    Bassanelli, Maria
    Iannicelli, Elsa
    Giacinti, Silvana
    D'Antonio, Chiara
    Aschelter, Anna Maria
    Marchetti, Paolo
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2015, 2015
  • [3] A phase II trial assessing pazopanib (paz) as third-line therapy for metastatic renal cell carcinoma (mRCC): Clinical outcome and temporal analysis of molecular profile
    Pal, Sumanta Kumar
    Hossain, Dewan Md Sakib
    Zhang, Qifang
    Gao, Chan
    Frankel, Paul Henry
    Ruel, Christopher
    Jones, Jeremy
    Carmichael, Courtney
    Twardowski, Przemyslaw
    Figlin, Robert A.
    Kortylewski, Marcin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Third-line Therapy for metastatic Renal cell carcinoma
    Rexer, H.
    ONKOLOGE, 2011, 17 (12): : 1161 - 1162
  • [5] Third-line Therapy for metastatic Renal Cell Carcinoma
    Rexer, H.
    UROLOGE, 2011, 50 (10): : 1319 - 1321
  • [6] Third-line dovitinib in metastatic renal cell carcinoma
    Schmidinger, Manuela
    LANCET ONCOLOGY, 2014, 15 (03): : 245 - 246
  • [7] Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
    Buchler, Tomas
    Bortlicek, Zbynek
    Poprach, Alexandr
    Kubackova, Katerina
    Kiss, Igor
    Zemanova, Milada
    Fiala, Ondrej
    Dusek, Ladislav
    Vyzula, Rostislav
    Melichar, Bohuslav
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 569 - 575
  • [8] Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma
    Hideaki Miyake
    Yuji Kusuda
    Ken-ichi Harada
    Iori Sakai
    Masato Fujisawa
    International Journal of Clinical Oncology, 2013, 18 : 81 - 86
  • [9] Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma
    Miyake, Hideaki
    Kusuda, Yuji
    Harada, Ken-ichi
    Sakai, Iori
    Fujisawa, Masato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (01) : 81 - 86
  • [10] Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Wells, J. Connor
    Stukalin, Igor
    Norton, Craig
    Srinivas, Sandy
    Lee, Jae Lyun
    Donskov, Frede
    Bjarnason, Georg A.
    Yamamoto, Haru
    Beuselinck, Benoit
    Rini, Brian I.
    Knox, Jennifer J.
    Agarwal, Neeraj
    Ernst, D. Scott
    Pal, Sumanta K.
    Wood, Lori A.
    Bamias, Aristotelis
    Alva, Ajjai S.
    Kanesvaran, Ravindran
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN UROLOGY, 2017, 71 (02) : 204 - 209
12345